Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey)

B Hoffmann, A Garcia de Lorenzo, A Mehta, M Beck, U Widmer, R Ricci, FOS European Investigators, B Hoffmann, A Garcia de Lorenzo, A Mehta, M Beck, U Widmer, R Ricci, FOS European Investigators

Abstract

Background: Fabry disease is an X linked lysosomal storage disease caused by deficiency of the lysosomal enzyme alpha-galactosidase A. This leads to accumulation of globotriaosylceramide in nearly all tissues, including the blood vessels, kidney, myocardium, and nervous system. Symptoms often begin in childhood and include acroparaesthesia, with burning or tingling pain that spreads from the extremities to more proximal sites.

Aims: This study set out to evaluate pain and its influence on quality of life in patients with Fabry disease receiving enzyme replacement therapy (ERT) with agalsidase alfa.

Methods: Data were obtained from the Fabry Outcome Survey. Pain was measured using the Brief Pain Inventory (BPI), and health-related quality of life (HRQoL) was documented with the European Quality of Life Questionnaire (EQ-5D).

Results: The mean (SD) score for "pain at its worst" on the BPI prior to ERT was 5.1 (2.7). One year after commencement of ERT, this had improved by 0.5, and improved by a further 0.6 after 2 years (p<0.05). Similar statistically significant improvements were seen for "pain on average" and "pain now" after 2 years of ERT. The mean HRQoL utility score prior to ERT was 0.66 (0.32). After 12 months of treatment with agalsidase alfa, this had improved to 0.74 (0.26; p<0.05); this improvement was maintained after 2 years.

Conclusions: ERT with agalsidase alfa significantly reduces pain and improves quality of life in patients with Fabry disease.

References

    1. J Clin Neurophysiol. 2002 Dec;19(6):575-86
    1. Z Kardiol. 2002 Oct;91(10):786-95
    1. Acta Paediatr Suppl. 2002;91(439):15-20
    1. Acta Paediatr Suppl. 2002;91(439):43-7
    1. Acta Paediatr Suppl. 2002;91(439):107-12
    1. Transplantation. 2003 Jul 15;76(1):176-82
    1. J Med Genet. 2003 Aug;40(8):e103
    1. Hum Mutat. 2003 Sep;22(3):258
    1. J Inherit Metab Dis. 2003;26(4):413-4
    1. Spine J. 2001 Mar-Apr;1(2):95-101
    1. Muscle Nerve. 2003 Dec;28(6):703-10
    1. Am J Kidney Dis. 2003 Dec;42(6):1239-47
    1. J Inherit Metab Dis. 2003;26(7):617-27
    1. Pain Med. 2003 Dec;4(4):305-7
    1. Drugs. 2003;63 Spec No 2:47-50
    1. Pain Med. 2004 Mar;5 Suppl 1:S9-S27
    1. Eur J Clin Invest. 2004 Mar;34(3):236-42
    1. J Pain. 2004 Mar;5(2):133-7
    1. Med Care. 1989 Mar;27(3 Suppl):S148-56
    1. Ann Acad Med Singapore. 1994 Mar;23(2):129-38
    1. Public Health Rep. 1994 Sep-Oct;109(5):665-72
    1. Soc Sci Med. 1994 Dec;39(11):1537-44
    1. Crit Care Med. 1996 Oct;24(10):1769
    1. Pain. 1997 Aug;72(1-2):235-43
    1. Qual Life Res. 1998 Feb;7(2):115-20
    1. JAMA. 1999 Jan 20;281(3):249-54
    1. Nature. 1961 Apr 22;190:372-3
    1. JAMA. 2000 Dec 6;284(21):2771-5
    1. Lancet. 2001 Jan 13;357(9250):138-40
    1. Med Care. 2001 Mar;39(3):217-27
    1. JAMA. 2001 Jun 6;285(21):2743-9
    1. Pharmacoeconomics. 2001;19(8):855-63
    1. Contrib Nephrol. 2001;(136):245-50
    1. J Med Genet. 2001 Nov;38(11):750-60
    1. J Inherit Metab Dis. 2001;24 Suppl 2:15-7; discussion 11-2
    1. J Inherit Metab Dis. 2001;24 Suppl 2:71-4; discussion 65
    1. Qual Life Res. 2001;10(6):479-86
    1. J Inherit Metab Dis. 2001 Dec;24(7):715-24
    1. Value Health. 2002 Jan-Feb;5(1):14-25
    1. Medicine (Baltimore). 2002 Mar;81(2):122-38
    1. Qual Life Res. 2002 Mar;11(2):127-33
    1. J Am Soc Nephrol. 2002 Jun;13 Suppl 2:S144-6
    1. J Am Soc Nephrol. 2002 Jun;13 Suppl 2:S147-9
    1. Qual Life Res. 2002 Jun;11(4):317-27
    1. Z Kardiol. 2002 Dec;91(12):992-1002

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe